Literature DB >> 27183219

Controlled attenuation parameter is correlated with actual hepatic fat content in patients with non-alcoholic fatty liver disease with none-to-mild obesity and liver fibrosis.

Naoyuki Fujimori1, Naoki Tanaka2, Soichiro Shibata1, Kenji Sano3, Tomoo Yamazaki1, Tomohiro Sekiguchi1, Hiroyuki Kitabatake1, Yuki Ichikawa1, Takefumi Kimura1, Michiharu Komatsu1, Takeji Umemura1, Akihiro Matsumoto1, Eiji Tanaka1.   

Abstract

AIM: Non-invasive steatosis-quantifying methods are required for non-alcoholic fatty liver disease (NAFLD) patients in order to monitor disease severity and assess therapeutic efficacy. Controlled attenuation parameter (CAP) evaluated with vibration-controlled transient elastography can predict the presence of steatosis, but its application to absolute hepatic fat quantitation remains unclear. The aim of this st\udy was to examine whether CAP is correlated with real hepatic fat content in NAFLD patients.
METHODS: Eighty-two NAFLD patients who had undergone percutaneous liver biopsy were enrolled. CAP was measured using FibroScan(®) just before liver biopsy. The percentage of fat droplet area to hepatocyte area in biopsied specimen was determined morphometrically using computerized optical image analyzing system. The correlation between CAP and liver histology was examined.
RESULTS: CAP showed an excellent correlation with actual liver fat percentage in the NAFLD patients with body mass index (BMI) of less than 28 kg/m(2) (r = 0.579, P < 0.0001), especially less than 25 kg/m(2) (r = 0.708, P < 0.01), but the meaningful correlation disappeared in the patients with BMI of 28 kg/m(2) or more. In the patients with BMI of less than 28 kg/m(2) , CAP quantitativeness was affected by the presence of stage 2-4 fibrosis, but not the presence of hepatocyte ballooning and severity of lobular inflammation.
CONCLUSION: CAP may be a promising tool for quantifying hepatic fat content in NAFLD patients with none-to-mild obesity and liver fibrosis. Further improvement of CAP performance is needed for the NAFLD patients with BMI of more than 28 kg/m(2) or significant hepatic fibrosis.
© 2016 The Japan Society of Hepatology.

Entities:  

Keywords:  body mass index; controlled attenuation parameter; fibrosis; liver fat; non-alcoholic fatty liver disease

Year:  2016        PMID: 27183219     DOI: 10.1111/hepr.12649

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  17 in total

1.  Growth arrest and DNA damage-inducible 45α protects against nonalcoholic steatohepatitis induced by methionine- and choline-deficient diet.

Authors:  Naoki Tanaka; Shogo Takahashi; Xiao Hu; Yu Lu; Naoyuki Fujimori; Srujana Golla; Zhong-Ze Fang; Toshifumi Aoyama; Kristopher W Krausz; Frank J Gonzalez
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-08-24       Impact factor: 5.187

2.  Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.

Authors:  Yu-Tian Cao; Liu-Lan Xiang; Fang Qi; Yu-Juan Zhang; Yi Chen; Xi-Qiao Zhou
Journal:  EClinicalMedicine       Date:  2022-07-10

3.  Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection.

Authors:  Lung-Yi Mak; Rex Wan-Hin Hui; James Fung; Fen Liu; Danny Ka-Ho Wong; Bofei Li; Ka-Shing Cheung; Man-Fung Yuen; Wai-Kay Seto
Journal:  Hepatol Int       Date:  2021-06-21       Impact factor: 6.047

Review 4.  The Use of Transient Elastography Technology in the Bariatric Patient: a Review of the Literature.

Authors:  Max M Puthenpura; Vishal Patel; John Fam; Leon Katz; David S Tichansky; Stephan Myers
Journal:  Obes Surg       Date:  2020-09-26       Impact factor: 4.129

5.  Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study.

Authors:  Satoshi Oeda; Hirokazu Takahashi; Kento Imajo; Yuya Seko; Yuji Ogawa; Michihisa Moriguchi; Masato Yoneda; Keizo Anzai; Shinichi Aishima; Masayoshi Kage; Yoshito Itoh; Atsushi Nakajima; Yuichiro Eguchi
Journal:  J Gastroenterol       Date:  2019-10-25       Impact factor: 7.527

6.  A prospective comparative assessment of the accuracy of the FibroScan in evaluating liver steatosis.

Authors:  Baek Gyu Jun; Won Young Park; Eui Ju Park; Jae Young Jang; Soung Won Jeong; Sae Hwan Lee; Sang Gyune Kim; Sang-Woo Cha; Young Seok Kim; Young Deok Cho; Hong Soo Kim; Boo Sung Kim; So Young Jin; Suyeon Park
Journal:  PLoS One       Date:  2017-08-15       Impact factor: 3.240

7.  The inverse effect of meal intake on controlled attenuation parameter and liver stiffness as assessed by transient elastography.

Authors:  Kanittha Ratchatasettakul; Sasivimol Rattanasiri; Kwannapa Promson; Pranee Sringam; Abhasnee Sobhonslidsuk
Journal:  BMC Gastroenterol       Date:  2017-04-13       Impact factor: 3.067

8.  A Noninvasive Score Model for Prediction of NASH in Patients with Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease.

Authors:  Jing Liang; Fang Liu; Fengmei Wang; Tao Han; Li Jing; Zhe Ma; Yingtang Gao
Journal:  Biomed Res Int       Date:  2017-03-02       Impact factor: 3.411

9.  Association between endotoxemia and histological features of nonalcoholic fatty liver disease.

Authors:  Hiroyuki Kitabatake; Naoki Tanaka; Naoyuki Fujimori; Michiharu Komatsu; Ayaka Okubo; Kyogo Kakegawa; Takefumi Kimura; Ayumi Sugiura; Tomoo Yamazaki; Soichiro Shibata; Yuki Ichikawa; Satoru Joshita; Takeji Umemura; Akihiro Matsumoto; Masayoshi Koinuma; Kenji Sano; Toshifumi Aoyama; Eiji Tanaka
Journal:  World J Gastroenterol       Date:  2017-01-28       Impact factor: 5.742

10.  Effect of skin-capsular distance on controlled attenuation parameter for diagnosing liver steatosis in patients with nonalcoholic fatty liver disease.

Authors:  Syunichiro Kimura; Kenichi Tanaka; Satoshi Oeda; Kaori Inoue; Chika Inadomi; Yoshihito Kubotsu; Wataru Yoshioka; Michiaki Okada; Hiroshi Isoda; Takuya Kuwashiro; Takumi Akiyama; Aya Kurashige; Ayaka Oshima; Mayumi Oshima; Yasue Matsumoto; Atsushi Kawaguchi; Keizo Anzai; Eisaburo Sueoka; Shinichi Aishima; Hirokazu Takahashi
Journal:  Sci Rep       Date:  2021-08-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.